Clinical trial · Interventional
Comparison of Single-Dose Tranexamic Acid Vs. Placebo in Ovarian Cancer Surgery
Comparison of Efficacy of Single Dose Tranexamic Acid Versus Placebo Before Surgery in Females Undergoing Surgery for Ovarian Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study evaluated the effectiveness of a single dose of tranexamic acid compared to a placebo in reducing blood loss and the need for blood transfusions in women undergoing surgery for ovarian cancer. Tranexamic acid, a medication that helps control bleeding by stabilizing blood clots, has been widely used in other surgical settings but has not been well studied in ovarian cancer surgery. Participants were randomly assigned to receive either a single dose of tranexamic acid or a placebo before surgery. Blood loss was measured during and after the procedure, and the need for blood transfusions was recorded. The study aimed to determine whether tranexamic acid was effective in reducing perioperative blood loss and minimizing the need for transfusions. The findings contributed to understanding whether this cost-effective and widely available medication could improve surgical outcomes and reduce complications associated with excessive bleeding in ovarian cancer patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Blood Transfusion Events | — | UNRESOLVED | — |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Perioperative Blood Loss | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebo | Drug | — | UNRESOLVED |
| Tranexamic Acid (TXA) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Group Tranexamic Acid
- description
- Participants in this group received a single preoperative intravenous dose of tranexamic acid at 15 mg/kg before undergoing surgery for ovarian cancer.
- interventionNames
- Drug: Tranexamic Acid (TXA)
- type
- PLACEBO_COMPARATOR
- label
- Group Placebo
- description
- Participants in this group received an equal volume of normal saline as a placebo intravenously before undergoing surgery for ovarian cancer.
- interventionNames
- Drug: Placebo
Primary outcomes (1)
- measure
- Requirement of Blood Transfusion After Surgery
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18-60. * Female gender. * Ovarian cancer of \> 12 months duration. * FIGO stage I-III. * American Society of Anesthesiologists (ASA) status 1-3. Exclusion Criteria: 1. Ovarian cancer of FIGO stage IV 2. ASA status 4-6. 3. Hypersensitivity to tranexamic acid, (assessed by reviewing previous medical record). 4. History of bleeding or clotting disorders (assessed by reviewing previous medical record). 5. Impaired renal function (serum creatinine \> 1.3 mg/dl). 6. History of coronary heart disease (assessed by reviewing previous medical record).
References
Publications (0)
Data not yet available